Organic compounds

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I), wherein V is specified in -O- or a single bond; W is specified in -N(R⁵)C(O)-, -S(O)_t- and -C(O)O-; X is specified in C(H) or N; Y is specified in S, N(H) or N(CH₃); p means 0 or 2; t means 1 or 2; R¹ is specified in a group consisting of hydrogen, C_1-6alkyl optionally substituted by 1 or 2 halogroups, C_3-7cycloalkylC_1-6alkyl, 2,3-dihydro-1H-indenyl, C₆arC_1-6alkyl optionally substituted by one or two halogroups and heteroarylC_1-6alkyl, wherein a heteroaryl fragment of the heteroarylalkyl group means 5-6-member monocyclic heteroaryl containing 1 or 2 heteroatoms independently specified in a group consisting of nitrogen optionally oxidated, oxygen and sulphur, or a heteroaryl fragment of the heteroarylalkyl group means 9-member bicyclic heteroaryl containing 1 or 2 heteroatoms independently specified in a group consisting of nitrogen, oxygen and sulphur, wherein monocyclic heteroaryl of the heteroarylalkyl group may be optionally substituted by one or two substitutes independently specified in a group consisting a halogroup, a cyanogroup, C_1-6alkyl, haloC_1-6alkyl and C_1-6alkyl-O-C(O)-; R² is specified in a group consisting of hydrogen, C_1-6alkyl optionally substituted by phenoxy, hydroxy C_1-6alkyl, C_3-7cycloalkyl, C_3-7cycloalkylC_1-6alkyl, phenyl optionally substituted by a halogroup, haloC_1-6alkyl, C₆arC_1-6alkyl (optionally substituted by a halogroup, haloC_1-6alkyl or haloC_1-6alkoxygroup), 2-oxo-imidazolidinyl, heterocyclylC_1-6alkyl and heteroarylC_1-6alkyl, wherein heterocyclyl of heterocyclylalkyl means 5- or 6-member monocycle containing oxygen, and wherein a heteroaryl fragment of the heteroarylalkyl group means 5-6-member monocycle containing 1-3 heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, or a heteroaryl fragment of the heteroarylalkyl group means 9- or 10-member bicycle containing 1 to 2 heteroatoms specified in a group consisting of nitrogen and sulphur, wherein monocyclic heteroaryl of the heteroaryl alkyl group may be optionally substituted by 1 or 2 substitutes independently specified in a group consisting of a halogroup, C_1-6alkyl, haloC_1-6alkyl and phenyl optionally substituted by a halogroup; R³ is specified in a group consisting of hydrogen and alkyl; two adjacent R⁴ groups together with carbon atoms whereto attached can form phenyl; R⁵ means hydrogen; or a pharmaceutically acceptable salt thereof.

EFFECT: preparing the heterocyclic derivatives which modulate activity of stearoyl CoA desaturase, methods of using the above derivatives for modulating activity of stearoyl CoA desaturase and pharmaceutical compositions containing the above derivatives.

26 cl, 1 tbl, 153 ex

The text descriptions are listed faxing

11.1. The compound of formula (I):
,
where V is chosen from-O - or a simple link;
W is selected from-N(R⁵)C(O)-, -S(O)_tand-C(O)O-;
X is chosen from C(H) or N;
Y is chosen from S, N(H) or N(CH₃);
p represents 0 or 2;
t represents 1 or 2;
R¹selected from the group including hydrogen, C_1-6alkyl, which is optionally substituted 1 or 2 holography,_3-7cycloalkyl_1-6alkyl, 2,3-dihydro-1H-indenyl,₆ARS_1-6alkyl, which is optionally substituted by one or two holography and heteroaryl_1-6alkyl, where the heteroaryl fragment heteroallyl group denotes a 5-6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, which is optionally oxidized, oxygen and sulfur, or heteroaryl fragment heteroallyl group refers to 9-membered bicyclic heteroaryl containing 1 or 2 heteroatoms independently selected is from the group comprising nitrogen, oxygen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by one or two substituents, independently selected from the group comprising halogroup, cyano, C_1-6alkyl, Gialos_1-6alkyl and C_1-6alkyl-O-C(O)-;
R²selected from the group including hydrogen, C_1-6alkyl, which is optionally substituted, phenoxy, hydroxy, C_1-6alkyl, C_3-7cycloalkyl,_3-7cycloalkyl_1-6alkyl, phenyl, which is optionally substituted by holography, Gialos_1-6alkyl, C₆ARS_1-6alkyl (which is optionally substituted by holography, Gialos_1-6the alkyl or Gialos_1-6alkoxygroup), 2-oxo-imidazolidinyl, heterocyclic_1-6alkyl and heteroaryl_1-6alkyl, where heterocyclyl of geterotsiklicheskikh denotes a 5 - or 6-membered monocycle containing oxygen, and where heteroaryl fragment heteroallyl group denotes a 5-6-membered monocycle containing from 1-3 heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, or heteroaryl fragment heteroallyl group denotes a 9 - or 10-membered Bicycle containing 1 to 2 heteroatoms selected from the group including nitrogen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by 1 or 2 substituents, independently selected the data from the group including holograph, C_1-6alkyl, Gialos_1-6alkyl and phenyl, which is optionally substituted by holography;
R³selected from the group comprising hydrogen and alkyl;
two adjacent R⁴group together with the carbon atoms to which they are attached may form a phenyl;
R⁵denotes hydrogen;
or its pharmaceutically acceptable salt.

2. The compound according to claim 1, or its pharmaceutically acceptable salt, where X denotes S(N) and Y represents S.

3. The compound according to claim 1, or its pharmaceutically acceptable salt, where X represents N and Y represents S.

4. The compound according to claim 1, or its pharmaceutically acceptable salt, where X represents N and Y represents N(H) or N(CH₃).

5. The compound according to claim 1, or its pharmaceutically acceptable salt, where V is chosen from-O - or a simple link;
W is selected from-N(R⁵)C(O)- or-C(O)O-;
X is chosen from C(H) or N;
Y is chosen from S, N(H) or N(CH₃);
p represents 0 or 2;
R¹selected from the group including hydrogen, C_1-6alkyl, which is optionally substituted 1 or 2 holography,₆ARS_1-6alkyl, which is optionally substituted by one or two holography, and heteroaryl_1-6alkyl, where the heteroaryl fragment heteroallyl group denotes a 5-6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group including the surrounding nitrogen, which is optionally oxidized, oxygen and sulfur, or heteroaryl fragment heteroallyl group refers to 9-membered bicyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, oxygen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by one or two substituents independently selected from the group comprising halogroup, cyano, C_1-6alkyl, Gialos_1-6alkyl and C_1-6alkyl-O-C(O)-;
R²selected from the group including hydrogen, C_1-6alkyl, hydroxys_1-6alkyl, C_3-7cycloalkyl,_3-7cycloalkyl_1-6alkyl, phenyl, which is optionally substituted by holography, Gialos_1-6alkyl, C₆ARS_1-6alkyl(which is optionally substituted by holography, Gialos_1-6the alkyl or Gialos_1-6alkoxygroup), 2-oxo-imidazolidinyl, heterocyclic_1-6alkyl and heteroaryl_1-6alkyl, where heterocyclyl of geterotsiklicheskikh denotes a 5 - or 6-membered monocycle containing oxygen, and where heteroaryl fragment heteroallyl group denotes a 5-6-membered monocycle containing from 1-3 heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, or heteroaryl fragment heteroallyl group denotes a 9 - or 10-membered Bicycle containing from 1 to heteroatoms, selected from the group including nitrogen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by 1 or 2 substituents, independently selected from the group comprising halogroup, C_1-6alkyl, Gialos_1-6alkyl and phenyl, which is optionally substituted by holography;
R³selected from the group comprising hydrogen and alkyl; and
R⁵denotes hydrogen.

6. The compound according to claim 2, or its pharmaceutically acceptable salt, where
V is selected from-O - or a simple link;
W is selected from-N(R⁵)C(O)- or-C(O)O-;
p represents 0 or 2;
R¹selected from the group including hydrogen, C_1-6alkyl, which is optionally substituted 1 or 2 holography, 2,3-dihydro-1H-indenyl,₆ARS_1-6alkyl, which is optionally substituted by one or two holography, and heteroaryl_1-6alkyl, where the heteroaryl fragment heteroallyl group denotes a 5-6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, which is optionally oxidized, oxygen and sulfur, or heteroaryl fragment heteroallyl group refers to 9-membered bicyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, oxygen and sulfur, where the monocyclic heteroaryl heteroarylboronic the group may be optionally substituted by one or two substituents, independently selected from the group comprising halogroup, cyano, C_1-6alkyl, Gialos_1-6alkyl and C_1-6alkyl-O-C(O)-;
R²selected from the group including hydrogen, C_1-6alkyl, hydroxys_1-6alkyl, C_3-7cycloalkyl,_3-7cycloalkyl_1-6alkyl, phenyl, which is optionally substituted by holography, Gialos_1-6alkyl, C₆ARS_1-6alkyl (which is optionally substituted by holography, Gialos_1-6the alkyl or Gialos_1-6alkoxygroup), 2-oxo-imidazolidinyl, heterocyclic_1-6alkyl and heteroaryl_1-6alkyl, where heterocyclyl of geterotsiklicheskikh denotes a 5 - or 6-membered monocycle containing oxygen, and where heteroaryl fragment heteroallyl group denotes a 5-6-membered monocycle containing from 1-3 heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, or heteroaryl fragment heteroallyl group denotes a 9 - or 10-membered Bicycle containing 1 to 2 heteroatoms selected from the group including nitrogen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by 1 or 2 substituents, independently selected from the group comprising halogroup, C_1-6alkyl, Gialos_1-6alkyl and phenyl, which is optionally substituted by holography;
R³selected from the group including hydrogen and al the sludge; and
R⁵denotes hydrogen.

7. The compound according to claim 3, or its pharmaceutically acceptable salt, where
V is selected from-O - or a simple link;
W is selected from-N(R⁵)C(O)- or-C(O)O-;
p represents 0 or 2;
R¹selected from the group including hydrogen, C_1-6alkyl, which is optionally substituted 1 or 2 holography, 2,3-dihydro-1H-indenyl,₆ARS_1-6alkyl, which is optionally substituted by one or two holography, and heteroaryl_1-6alkyl, where the heteroaryl fragment heteroallyl group denotes a 5-6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, which is optionally oxidized, oxygen and sulfur, or heteroaryl fragment heteroallyl group refers to 9-membered bicyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, oxygen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by one or two substituents, independently selected from the group comprising halogroup, cyano, C_1-6alkyl, Gialos_1-6alkyl and C_1-6alkyl-O-C(O)-;
R²selected from the group including hydrogen, C_1-6alkyl, hydroxys_1-6alkyl, C_3-7cycloalkyl,_3-7cycloalkyl_1-6alkyl, phenyl, which is optionally substituted by holography, Gialos_1-6alkyl, C₆ARS_1-6alkyl, which is optionally substituted by holography, Gialos_1-6the alkyl or Gialos_1-6alkoxygroup, 2-oxo-imidazolidinyl, heterocyclic_1-6alkyl and heteroaryl_1-6alkyl, where heterocyclyl of geterotsiklicheskikh denotes a 5 - or 6-membered monocycle containing oxygen, and where heteroaryl fragment heteroallyl group denotes a 5-6-membered monocycle containing from 1-3 heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, or heteroaryl fragment heteroallyl group denotes a 9 - or 10-membered Bicycle containing 1 to 2 heteroatoms selected from the group including nitrogen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by 1 or 2 substituents, independently selected from the group comprising halogroup, C_1-6alkyl, Gialos_1-6alkyl and phenyl, which is optionally substituted by holography;
R³selected from the group comprising hydrogen and alkyl;
two adjacent R⁴group together with the carbon atoms to which they are attached may form a phenyl; and
R⁵denotes hydrogen.

8. The connection according to claim 7, or its pharmaceutically acceptable salt, where
V denotes a simple link;
W represents-N(R⁵)C(O)-;
p represents 0 or 2;
R¹selected from the group comprising hydrogen, C_1-6alkyl, which is optionally substituted 1 or 2 holography, 2,3-dihydro-1H-indenyl,₆ARS_1-6alkyl, which is optionally substituted by one or two holography, and heteroaryl_1-6alkyl, where the heteroaryl fragment heteroallyl group denotes a 5-6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, which is optionally oxidized, oxygen and sulfur, or heteroaryl fragment heteroallyl group refers to 9-membered bicyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, oxygen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by one or two substituents independently selected from the group comprising halogroup, cyano, C_1-6alkyl, Gialos_1-6alkyl and C_1-6alkyl-O-C(O)-;
R²selected from the group including hydrogen, C_1-6alkyl, hydroxys_1-6alkyl, C_3-7cycloalkyl,_3-7cycloalkyl_1-6alkyl, phenyl, which is optionally substituted by holography, Gialos_1-6alkyl, C₆ARS_1-6alkyl(which is optionally substituted by holography, Gialos_1-6the alkyl or Gialos_1-6alkoxygroup), 2-oxo-imidazolidinyl, heterocyclic_1-6alkyl and heteroaryl_{1-6/sub> alkyl, where heterocyclyl of geterotsiklicheskikh denotes a 5 - or 6-membered monocycle containing oxygen, and where heteroaryl fragment heteroallyl group denotes a 5-6-membered monocycle containing from 1-3 heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, or heteroaryl fragment heteroallyl group denotes a 9 - or 10-membered Bicycle containing 1 to 2 heteroatoms selected from the group including nitrogen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by 1 or 2 substituents, independently selected from the group comprising halogroup, C1-6alkyl, Gialos1-6alkyl and phenyl, which is optionally substituted by holography;
R³selected from the group comprising hydrogen and alkyl;
two adjacent R⁴group together with the carbon atoms to which they are attached may form a phenyl; and
R⁵denotes hydrogen.}

9. The connection according to claim 7, or its pharmaceutically acceptable salt, where
V represents-O-;
W represents-N(R⁵)C(O)-;
p represents 0 or 2;
R¹selected from the group including hydrogen, C_1-6alkyl, which is optionally substituted 1 or 2 holography, 2,3-dihydro-1H-indenyl,₆ARS_1-6alkyl, which is optionally substituted by one or two holography, and heteroaryl_1-6alkyl, where GE is ereally fragment heteroallyl group denotes a 5-6-membered monocyclic heteroaryl, containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, which is optionally oxidized, oxygen and sulfur, or heteroaryl fragment heteroallyl group refers to 9-membered bicyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, oxygen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by one or two substituents, independently selected from the group comprising halogroup, cyano, C_1-6alkyl, Gialos_1-6alkyl and C_1-6alkyl-O-C(O)-;
R²selected from the group including hydrogen, C_1-6alkyl, hydroxys_1-6alkyl, C_3-7cycloalkyl,_3-7cycloalkyl_1-6alkyl, phenyl, which is optionally substituted by holography, Gialos_1-6alkyl, C₆ARS_1-6alkyl, which is optionally substituted by holography, Gialos_1-6the alkyl or Gialos_1-6alkoxygroup, 2-oxo-imidazolidinyl, heterocyclic_1-6alkyl and heteroaryl_1-6alkyl, where heterocyclyl of geterotsiklicheskikh denotes a 5 - or 6-membered monocycle containing oxygen, and where heteroaryl fragment heteroallyl group denotes a 5-6-membered monocycle containing from 1-3 heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, or heteroaryl fragment GE is erourolliou group denotes a 9 - or 10-membered Bicycle, containing 1 to 2 heteroatoms selected from the group including nitrogen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by 1 or 2 substituents, independently selected from the group comprising halogroup, C_1-6alkyl, Gialos_1-6alkyl and phenyl, which is optionally substituted by holography;
R³selected from the group comprising hydrogen and alkyl;
two adjacent R⁴group together with the carbon atoms to which they are attached may form a phenyl; and R⁵denotes hydrogen.
The compound according to claim 4, or pharmaceutically acceptable salt,
where V is chosen from-O - or a simple link;
W is selected from-N(R⁵)C(O)- or-C(O)O-;
p represents 0 or 2;
R¹selected from the group including hydrogen, C_1-6alkyl, which is optionally substituted 1 or 2 holography, 2,3-dihydro-1H-indenyl,₆ARS_1-6alkyl, which is optionally substituted by one or two holography, and heteroaryl_1-6alkyl, where the heteroaryl fragment heteroallyl group denotes a 5-6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, which is optionally oxidized, oxygen and sulfur, or heteroaryl fragment heteroallyl group refers to 9-membered bicyclic heteroaryl containing 1 or 2 heteroatom, independently selected from the group comprising nitrogen, oxygen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by one or two substituents, independently selected from the group comprising halogroup, cyano, C_1-6alkyl, Gialos_1-6alkyl and C_1-6alkyl-O-C(O)-;
R²selected from the group including hydrogen, C_1-6alkyl, hydroxys_1-6alkyl, C_3-7cycloalkyl,_3-7cycloalkyl_1-6alkyl, phenyl, which is optionally substituted by holography, Gialos_1-6alkyl, C₆ARS_1-6alkyl, which is optionally substituted by holography, Gialos_1-6the alkyl or Gialos_1-6alkoxygroup, 2-oxo-imidazolidinyl, heterocyclic_1-6alkyl and heteroaryl_1-6alkyl, where heterocyclyl of geterotsiklicheskikh denotes a 5 - or 6-membered monocycle containing oxygen, and where heteroaryl fragment heteroallyl group denotes a 5-6-membered monocycle containing from 1-3 heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, or heteroaryl fragment heteroallyl group denotes a 9 - or 10-membered Bicycle containing 1 to 2 heteroatoms selected from the group including nitrogen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by 1 or 2 substituents, the independent is selected from the group including holograph, C_1-6alkyl, Gialos_1-6alkyl and phenyl, which is optionally substituted by holography;
R³selected from the group comprising hydrogen and alkyl;
two adjacent R⁴group together with the carbon atoms to which they are attached may form a phenyl; and
R⁵denotes hydrogen.

11. The compound according to claim 1, or its pharmaceutically acceptable salt,
where V is chosen from-O - or a simple link;
W is selected from-N(R⁵)C(O)- or-C(O)O-;
X is chosen from C(H) or N;
Y is chosen from S, N(H) or N(CH₃);
p represents 0 or 2;
R¹selected from the group including hydrogen, C_1-6alkyl, which is optionally substituted 1 or 2 holography, 2,3-dihydro-1H-indenyl,₆ARS_1-6alkyl, which is optionally substituted by one or two holography, and heteroaryl_1-6alkyl, where the heteroaryl fragment heteroallyl group denotes a 5-6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, which is optionally oxidized, oxygen and sulfur, or heteroaryl fragment heteroallyl group refers to 9-membered bicyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, oxygen and sulfur, where the monocyclic heteroaryl heteroallyl group can be neo is Astelin substituted by one or two substituents, independently selected from the group comprising halogroup, cyano, C_1-6alkyl, Gialos_1-6alkyl and C_1-6alkyl-O-C(O)-;
R²selected from the group including hydrogen, C_1-6alkyl, hydroxys_1-6alkyl, C_3-7cycloalkyl,_3-7cycloalkyl_1-6alkyl, phenyl, which is optionally substituted by holography, Gialos_1-6alkyl, C₆ARS_1-6alkyl, which is optionally substituted by holography, Gialos_1-6the alkyl or Gialos_1-6alkoxygroup, 2-oxo-imidazolidinyl, heterocyclic_1-6alkyl and heteroaryl_1-6alkyl, where heterocyclyl of geterotsiklicheskikh denotes a 5 - or 6-membered monocycle containing oxygen, and where heteroaryl fragment heteroallyl group denotes a 5-6-membered monocycle containing from 1-3 heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, or heteroaryl fragment heteroallyl group denotes a 9 - or 10-membered Bicycle containing 1 to 2 heteroatoms selected from the group including nitrogen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by 1 or 2 substituents, independently selected from the group comprising halogroup, C_1-6alkyl, Gialos_1-6alkyl and phenyl, which is optionally substituted by holography;
R³selected from the group comprising hydrogen and ALK is l; and
R⁵denotes hydrogen.

12. The compound according to claim 2, or its pharmaceutically acceptable salt,
where V is chosen from-O - or a simple link;
W is selected from-N(R⁵)C(O)- or-C(O)O-;
p represents 0 or 2;
R¹selected from the group including hydrogen, C_1-6alkyl, which is optionally substituted 1 or 2 holography, 2,3-dihydro-1H-indenyl,₆ARS_1-6alkyl, which is optionally substituted by one or two holography, and heteroaryl_1-6alkyl, where the heteroaryl fragment heteroallyl group denotes a 5-6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, which is optionally oxidized, oxygen and sulfur, or heteroaryl fragment heteroallyl group refers to 9-membered bicyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, oxygen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by one or two substituents, independently selected from the group comprising halogroup, cyano, C_1-6alkyl, Gialos_1-6alkyl and C_1-6alkyl-O-C(O)-;
R²selected from the group including hydrogen, C_1-6alkyl, hydroxys_1-6alkyl, C_3-7cycloalkyl,_3-7cycloalkyl_1-6alkyl, phenyl, which is th optionally substituted by holography, Gialos_1-6alkyl, C₆ARS_1-6alkyl, which is optionally substituted by holography, Gialos_1-6the alkyl or Gialos_1-6alkoxygroup, 2-oxo-imidazolidinyl, heterocyclic_1-6alkyl and heteroaryl_1-6alkyl, where heterocyclyl of geterotsiklicheskikh denotes a 5 - or 6-membered monocycle containing oxygen, and where heteroaryl fragment heteroallyl group denotes a 5-6-membered monocycle containing from 1-3 heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, or heteroaryl fragment heteroallyl group denotes a 9 - or 10-membered Bicycle containing 1 to 2 heteroatoms selected from the group including nitrogen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by 1 or 2 substituents, independently selected from the group comprising halogroup, C_1-6alkyl, Gialos_1-6alkyl and phenyl, which is optionally substituted by holography;
R³selected from the group comprising hydrogen and alkyl; and
R⁵denotes hydrogen.

13. The compound according to claim 3, or its pharmaceutically acceptable salt,
where V is chosen from-O - or a simple link;
W is selected from-N(R⁵)C(O)- or-C(O)O-;
p represents 0 or 2;
R¹selected from the group including hydrogen, C_1-6alkyl, which is optionally substituted 1 or 2 holography, 2,3-Digi the ro-1H-indenyl, With₆ARS_1-6alkyl, which is optionally substituted by one or two holography, and heteroaryl_1-6alkyl, where the heteroaryl fragment heteroallyl group denotes a 5-6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, which is optionally oxidized, oxygen and sulfur, or heteroaryl fragment heteroallyl group refers to 9-membered bicyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, oxygen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by one or two substituents, independently selected from the group comprising halogroup, cyano, C_1-6alkyl, Gialos_1-6alkyl and C_1-6alkyl-O-C(O)-;
R²selected from the group including hydrogen, C_1-6alkyl, hydroxys_1-6alkyl, C_3-7cycloalkyl,_3-7cycloalkyl_1-6alkyl, phenyl, which is optionally substituted by holography, Gialos_1-6alkyl, C₆ARS_1-6alkyl, which is optionally substituted by holography, Gialos_1-6the alkyl or Gialos_1-6alkoxygroup, 2-oxo-imidazolidinyl, heterocyclic_1-6alkyl and heteroaryl_1-6alkyl, where heterocyclyl of geterotsiklicheskikh denotes a 5 - or 6-membered monocycle, sod is Rashi oxygen, and where heteroaryl fragment heteroallyl group denotes a 5-6-membered monocycle containing from 1-3 heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, or heteroaryl fragment heteroallyl group denotes a 9 - or 10-membered Bicycle containing 1 to 2 heteroatoms selected from the group including nitrogen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by 1 or 2 substituents, independently selected from the group comprising halogroup, C_1-6alkyl, Gialos_1-6alkyl and phenyl, which is optionally substituted by holography;
R³selected from the group comprising hydrogen and alkyl; and
R⁵denotes hydrogen.

14. The compound according to claim 4, or pharmaceutically acceptable salt,
where V is chosen from-O - or a simple link;
W is selected from-N(R⁵)C(O)- or-C(O)O-;
p represents 0 or 2;
R¹selected from the group including hydrogen, C_1-6alkyl, which is optionally substituted 1 or 2 holography, 2,3-dihydro-1H-indenyl,₆ARS_1-6alkyl, which is optionally substituted by one or two holography, and heteroaryl_1-6alkyl, where the heteroaryl fragment heteroallyl group denotes a 5-6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, to the verge optionally oxidized, oxygen and sulfur, or heteroaryl fragment heteroallyl group refers to 9-membered bicyclic heteroaryl containing 1 or 2 heteroatoms, independently selected from the group comprising nitrogen, oxygen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by one or two substituents, independently selected from the group comprising halogroup, cyano, C_1-6alkyl, Gialos_1-6alkyl and C_1-6alkyl-O-C(O)-;
R²selected from the group including hydrogen, C_1-6alkyl, hydroxys_1-6alkyl, C_3-7cycloalkyl,_3-7cycloalkyl_1-6alkyl, phenyl, which is optionally substituted by holography, Gialos_1-6alkyl, C₆ARS_1-6alkyl, which is optionally substituted by holography, Gialos_1-6the alkyl or Gialos_1-6alkoxygroup, 2-oxo-imidazolidinyl, heterocyclic_1-6alkyl and heteroaryl_1-6alkyl, where heterocyclyl of geterotsiklicheskikh denotes a 5 - or 6-membered monocycle containing oxygen, and where heteroaryl fragment heteroallyl group denotes a 5-6-membered monocycle containing from 1-3 heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, or heteroaryl fragment heteroallyl group denotes a 9 - or 10-membered Bicycle containing 1 to 2 heteroatoms selected from the group is s, including the nitrogen and sulfur, where the monocyclic heteroaryl heteroallyl group may be optionally substituted by 1 or 2 substituents, independently selected from the group comprising halogroup, C_1-6alkyl, Gialos_1-6alkyl and phenyl, which is optionally substituted by holography;
R³selected from the group comprising hydrogen and alkyl; and
R⁵denotes hydrogen.

15. The compound is chosen from the group including:
N-benzyl-4-methyl-2-(2-oxo-4-phenylpyridine-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-2-(5-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-(4-chlorophenyl)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-(cyclopropylmethoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-methoxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-(4-terbisil)-2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-(2-cyclopropylmethoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
2-(4-amino-2-oxopyridine-1(2H)-yl)-N-benzyl-4-methylthiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxopyridine-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-(phenylcarbamoyl)pyridine-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-2-(3-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxym is d;
N-benzyl-2-(3-hydroxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-3-(phenylcarbamoyl)pyridine-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-5-(phenylcarbamoyl)pyridine-1(2H)-yl)thiazole-5-carboxamide;
2-(4-benzamido-2-oxopyridine-1(2H)-yl)-N-benzyl-4-methylthiazole-5-carboxamide;
N-(4-terbisil)-4-methyl-2-(2-oxopyridine-1(2H)-yl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-N-(4-terbisil)-4-methylthiazole-5-carboxamide;
2-(4-(2-cyclopropylmethoxy)-2-oxopyridine-1(2H)-yl)-N-(4-terbisil)-4-methylthiazole-5-carboxamide;
2-(4-(2-cyclopropylmethoxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-(pyridine-3-ylmethyl)thiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-(pyridine-3-ylethoxy)pyridine-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-2-(5-hydroxy-1-oxoethyl-2(1H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(6-hydroxy-1-exogenesis-1(2H)yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(6-(benzyloxy)-2-oxoindole-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(5-(benzyloxy)-l-exogenesis-2(1H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-1H-imidazol-5-carboxamide;
N-benzyl-5-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-3-methylthiophene-2-carboxamide;
N-benzyl-5-(4-hydroxy-2-oxopyridine-1(2H)-yl)-3-methylthiophene-2-carboxamide;
N-benzyl-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-1,4-dimethyl-1H-imidazol-5-to Roxane;
N-benzyl-5-(4-(2-cyclopropylmethoxy)-2-oxopyridine-1(2H)-yl)-3-methylthiophene-2-carboxamide;
ethyl-4-methyl-2-(2-oxo-4-phenylpyridine-1(2H)-yl)thiazole-5-carboxylate;
ethyl-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxylate;
ethyl-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-1H-imidazole-5-carboxylate;
ethyl-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-1,4-dimethyl-1H-imidazole-5-carboxylate;
4-methyl-2-(2-oxo-4-phenylpyridine-1(2H)-yl)thiazole-5-carboxylic acid;
4-methyl-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)thiazole-5-carboxylic acid;
2-(4-(cyclopropylmethoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxylic acid;
2-(4-(2-cyclopropylmethoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxylic acid;
2-(4-methoxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxylic acid;
2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxylic acid;
ethyl-2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxylate;
ethyl-2-(4-(cyclopropylmethoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxylate;
ethyl-2-(4-methoxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxylate;
ethyl-2-(4-(2-cyclopropylmethoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxylate;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-1H-imidazole-5-carboxylic acid;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-1,4-dimethyl-1H-imidazole-5-carboxylic acid;
2-(4-(benzyloxy)-2-oxopyridine-N)-yl)-4-methyl-N-(pyridine-3-ylmethyl)-1H-imidazol-5-carboxamide;
N-benzyl-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-5-(trifluoromethyl)pyridine-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-3-(trifluoromethyl)pyridine-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-(trifluoromethyl)pyridine-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-(pyridine-2-ylethoxy)pyridine-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-3-methyl-5-(2-oxo-4-(4-(trifluoromethyl)benzyloxy)pyridine-1(2H)-yl)thiophene-2-carboxamide;
N-benzyl-5-(4-(4-forbindelse)-2-oxopyridine-1(2H)-yl)-3-methylthiophene-2-carboxamide;
N-benzyl-5-(4-(4-(deformedarse)benzyloxy)-2-oxopyridine-1(2H)-yl)-3-methylthiophene-2-carboxamide;
N-benzyl-3-methyl-5-(2-oxo-4-pentoxifyllin-1(2H)-yl)thiophene-2-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-((5-(trifluoromethyl)furan-2-yl)methoxy)pyridin-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-2-(4-(4-forbindelse)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-(pyridine-3-ylmethyl)thiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-(4-(trifluoromethyl)benzyloxy)pyridine-1(2H)-yl)thiazole-5-carboxamide;
2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methyl-N-(pyridine-3-ylmethyl)thiazole-5-carboxamide;
N-(3-terbisil)-2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-(cyclopropylmethyl)-2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-CT is the oksamid;
4-methyl-2-(2-oxopyridine-1(2H)-yl)-N-(pyridine-3-ylmethyl)thiazole-5-carboxamide;
N-(2-cyclopropylethyl)-2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-(4-florfenicol)-2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-peneteneries-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-phenoxypyridine-1(2H)-yl)thiazole-5-carboxamide;
4-methyl-2-(2-oxo-4-(trifluoromethyl)pyridine-1(2H)-yl)-N-(pyridine-3-ylmethyl)thiazole-5-carboxamide;
N-(3,4-diferensial)-2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-(2-Oxymetazoline-1-yl)pyridine-1(2H)-yl)-thiazole-5-carboxamide;
2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methyl-N-(pyridine-4-ylmethyl)thiazole-5-carboxamide;
2-(4-(4-(deformedarse)benzyloxy)-2-oxopyridine-1(2H)-yl)-N-(4-terbisil)-4-methylthiazole-5-carboxamide;
2-(4-methoxy-2-oxopyridine-1(2H)-yl)-4-methyl-N-(pyridine-3-ylmethyl)thiazole-5-carboxamide;
4-methyl-2-(2-oxo-4-((5-(trifluoromethyl)furan-2-yl)methoxy)pyridin-1(2H)-yl)-N-(pyridine-3-ylmethyl)thiazole-5-carboxamide;
2-(4-(4-forbindelse)-2-oxopyridine-1(2H)-yl)-4-methyl-N-(pyridine-3-ylmethyl)thiazole-5-carboxamide;
N-(4-terbisil)-2-(4-(4-forbindelse)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-(cyclopentyloxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-(3,4-diferensial)-2-(4-methoxy-2-occupied is -1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-(phenoxymethyl)pyridine-1(2H)-yl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-N-(3,4-diferensial)-4-methylthiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-((tetrahydrofuran-2-yl)methoxy)pyridin-1(2H)-yl)thiazole-5-carboxamide;
3-((2-(4-methoxy-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamido)methyl)pyridine-1-oxide;
N-benzyl-4-methyl-2-(2-oxo-4-((5-phenyl-1,3,4-oxadiazol-2-yl)methoxy)pyridin-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-2-(4-((5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)methoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-((4-chloro-2-(trifluoromethyl)quinoline-6-yl)methoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridin-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-(thiazol-4-ylethoxy)pyridine-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-4-methyl-2-(2-oxo-4-((tetrahydro-2H-Piran-2-yl)methoxy)pyridin-1(2H)-yl)thiazole-5-carboxamide;
N-(benzo[b]thiophene-2-ylmethyl)-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-((3-methylthiophene-2-yl)methyl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-N-(2,3-dihydro-N-inden-2-yl)-4-methylthiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-((5-methylpyridin-2-yl)methyl)thiazole-5-carboxamide;
2-(4-(benzyloxy-2-oxopyridine-1(2H)-yl)-4-methyl-N-(oxazol-2-ylmethyl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-((5-methyl-2-(trifluoromethyl)furan-3-yl)methyl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-(thiazol-2-ylmethyl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-((5-methylthiophene-2-yl)methyl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-((4-methylthiophene-2-yl)methyl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-N-((1,5-dimethyl-N-pyrrol-2-yl)methyl)-4-methylthiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-((1-methyl-1H-imidazol-5-yl)methyl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-((1-methyl-1H-pyrazole-4-yl)methyl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-((2-methylthiazole-4-yl)methyl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-N-((5-cianfuran-2-yl)methyl)-4-methylthiazole-5-carboxamide;
N-(benzo[d]oxazol-2-ylmethyl)-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
ethyl-5-((2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamido)methyl)furan-2-carboxylate;
N-((1H-indol-2-yl)methyl)-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-(benzo[d]thiazol-2-ylmethyl)-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-((1H-pyrazole-3-yl)methyl)-2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carb is camid;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-N-((6-chloropyridin-3-yl)methyl)-4-methylthiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)thiazole-5-carboxamide;
2-(4-(benzyloxy)-2-oxopyridine-1(2H)-yl)-4-methyl-N-((5-methylfuran-2-yl)methyl)thiazole-5-carboxamide;
N-benzyl-4-methyl-2-(4-((5-methylisoxazol-3-yl)methoxy)-2-oxopyridine-1(2H)-yl)thiazole-5-carboxamide;
N-benzyl-2-(4-((5-chlorothiophene-2-yl)methoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-((5-chlorothiophene-2-yl)methoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-((2-isopropylthiazole-4-yl)methoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-((6-chloropyridin-3-yl)methoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
N-benzyl-4-methyl-2-(4-((2-methylthiazole-4-yl)methoxy)-2-oxopyridine-1(2H)-yl)thiazole-5-carboxamide;
2-(4-((1,2,4-oxadiazol-3-yl)methoxy)-2-oxopyridine-1(2H)-yl)-N-benzyl-4-methylthiazole-5-carboxamide;
N-benzyl-2-(4-((3,5-dimethylisoxazol-4-yl)methoxy)-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide;
2-(4-hydroxy-2-oxopyridine-1(2H)-yl)-4-methyl-N-(oxazol-2-ylmethyl)thiazole-5-carboxamide; and
N-benzyl-2-(4-cyclopropyl-2-oxopyridine-1(2H)-yl)-4-methylthiazole-5-carboxamide, or its pharmaceutically acceptable salt.

16. Pharmaceutical composition for inhibiting the activity of stearoyl-SOA of desaturase, who with a compound of formula (I) according to any one of claims 1 to 15 or its pharmaceutically acceptable salt, and pharmaceutically acceptable excipient or carrier.

17. A method of inhibiting the activity of human stearoyl-SOA of desaturase (hSCD), which consists in contacting the source of hSCD with a compound according to any one of claims 1 to 15 or its pharmaceutically acceptable salt.

18. The use of the compounds of formula (I) according to any one of claims 1 to 15 or its pharmaceutically acceptable salt to obtain a pharmaceutical composition for the treatment of illness or disease in a subject mediated inhibition of stearoyl-SOA of desaturase.

19. Use p, where the disease or condition is metabolic syndrome, syndrome X, diabetes, insulin resistance, decreased glucose tolerance, non-insulin-dependent diabetes mellitus, type II diabetes, type I diabetes, diabetic complications, disorders of body weight, loss weight, body mass index, or leptin related diseases.

20. The application of claim 19, where the metabolic syndrome is dyslipidemia, obesity, insulin resistance, hypertension, microalbuminemia, hyperuricemia or hypercoagulable.

21. Use p, where the disease body mass refers to obesity, overweight, cachexia or anorexia.

22. Use p where disease or disease is a skin disease.

23. The application of article 22, where the skin disease is one the Xia eczema, acne, psoriasis, or education, or prevention of keloid scars.

24. The compound of formula (I) according to any one of claims 1 to 15 for use as a medicinal product with the activity of stearoyl-SOA of desaturase.

25. Pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 15 or its pharmaceutically acceptable salt, pharmaceutically acceptable excipient or carrier, for use as a medicinal product with the activity of stearoyl-SOA of desaturase.

26. The use of the pharmaceutical composition according to item 16 or 25 to obtain drugs for the treatment of illness or disease in a subject mediated inhibition of stearoyl-SOA of desaturase.